Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes involved in the regrowth of clinically non-functioning pituitary adenoma
- PMID: 32015217
- PMCID: PMC7041752
- DOI: 10.18632/aging.102751
Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes involved in the regrowth of clinically non-functioning pituitary adenoma
Abstract
Tumour regrowth is a key characteristic of clinically non-functioning pituitary adenoma (NFPA). No applicable prognosis evaluation method is available for post-operative patients. We aimed to identify DNA methylation biomarkers that can facilitate prognosis evaluation. Genome-wide DNA methylation and mRNA microarray analyses were performed for tumour samples from 71 NFPA patients. Differentially expressed genes and methylated genes were identified based on the regrowth vs non-regrowth grouping. There were 139 genes that showed alterations in methylation status and expression level, and only 13 genes showed a negative correlation. The progression-free analysis found that FAM90A1, ETS2, STAT6, MYT1L, ING2 and KCNK1 are related to tumour regrowth. A prognosis-prediction model was built based on all 13 genes from integrated analysis, and the 6-gene model achieved the best area under the receiver operating characteristic curves (AUC) of 0.820, compared with 0.785 and 0.568 for the 13-gene and 7-gene models, respectively. Our prognostic biomarkers were validated by pyrosequencing and RT-PCR. FAM90A1 and ING2 was found to be independent prognostic factors of tumour regrowth with univariate Cox regression. The DNA methylation and expression levels of FAM90A1 and ING2 are associated with tumour regrowth, and may serve as biomarkers for predicting the prognosis of patients with NFPA.
Keywords: DNA methylation; clinically non-functioning pituitary adenoma; regrowth prediction.
Conflict of interest statement
Figures






Similar articles
-
Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles.J Transl Med. 2019 Dec 3;17(1):407. doi: 10.1186/s12967-019-02148-3. J Transl Med. 2019. PMID: 31796052 Free PMC article.
-
Predicting the regrowth of clinically non-functioning pituitary adenoma with a statistical model.J Transl Med. 2019 May 20;17(1):164. doi: 10.1186/s12967-019-1915-2. J Transl Med. 2019. PMID: 31109334 Free PMC article.
-
Identification of a multidimensional transcriptome signature predicting tumor regrowth of clinically non‑functioning pituitary adenoma.Int J Oncol. 2020 Sep;57(3):804-812. doi: 10.3892/ijo.2020.5087. Epub 2020 Jun 23. Int J Oncol. 2020. PMID: 32582995
-
Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review.Breast Cancer Res. 2020 Jan 31;22(1):13. doi: 10.1186/s13058-020-1250-9. Breast Cancer Res. 2020. PMID: 32005275 Free PMC article.
-
PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer.Medicine (Baltimore). 2019 Jan;98(1):e13820. doi: 10.1097/MD.0000000000013820. Medicine (Baltimore). 2019. PMID: 30608394 Free PMC article.
Cited by
-
Overexpressed KCNK1 regulates potassium channels affecting molecular mechanisms and biological pathways in bladder cancer.Eur J Med Res. 2024 Apr 30;29(1):257. doi: 10.1186/s40001-024-01844-1. Eur J Med Res. 2024. PMID: 38689322 Free PMC article.
-
Current understanding of the role of DNA methylation in pituitary neuroendocrine tumors.Neurooncol Adv. 2025 Jan 2;7(Suppl 1):i2-i9. doi: 10.1093/noajnl/vdae149. eCollection 2025 Jul. Neurooncol Adv. 2025. PMID: 40718392 Free PMC article.
-
Characterization and comparison of insulinoma tumor model and pancreatic damage caused by the tumor, and identification of possible markers.Mol Biol Rep. 2024 Jan 16;51(1):109. doi: 10.1007/s11033-023-08942-z. Mol Biol Rep. 2024. PMID: 38227104
-
What Role Does CFTR Play in Development, Differentiation, Regeneration and Cancer?Int J Mol Sci. 2020 Apr 29;21(9):3133. doi: 10.3390/ijms21093133. Int J Mol Sci. 2020. PMID: 32365523 Free PMC article. Review.
-
Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors.J Endocrinol Invest. 2023 Apr;46(4):727-747. doi: 10.1007/s40618-022-01923-2. Epub 2022 Oct 28. J Endocrinol Invest. 2023. PMID: 36306107
References
-
- Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: primary brain and other central nervous system tumors diagnosed in the United States in 2010-2014. Neuro-oncol. 2017. (suppl_5); 19:v1–88. 10.1093/neuonc/nox158 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous